US expert publishes review on the prevention of surgical site infection (SSI), endorsing the value of nasal decolonisation of S. aureus/MRSA. Dr Deverick Anderson, Professor of Medicine at Duke University, USA & Director of the Duke Center for Antimicrobial Stewardship and Infection Prevention, and colleagues published a paper entitled ‘Surgical Site Infection Prevention: A Review’ in JAMA (Journal of the American Medical Association) based on a large scientific literature search covering 2016 to 2022. Click here for review.
In the review Dr Anderson underlines that SSIs are predominantly caused by S. aureus/MRSA with US hospitals suffering up to 500,000 such SSIs a year at a cost of $10 billion to the US healthcare system. He reviews and comments on the latest data which supports nasal decolonisation of S. aureus/MRSA in patients undergoing surgery as a valuable SSI preventive intervention, stating that a rapid decolonisation immediately ahead of surgery is most desirable and effective.
Destiny Pharma’s lead candidate, XF-73, is a novel drug targeting nasal decolonisation heading towards P3 studies.
A podcast is available where Dr Anderson discusses his findings in great detail. Click here for podcast.